WithdrawnNot applicableNCT01614171
Growth Hormone for Osteoporosis Pseudoglioma Syndrome
Studying Osteoporosis-pseudoglioma syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Maryland, Baltimore
- Principal Investigator
- Elizabeth A Streeten, MD, MDUniversity of Maryland School of Medicine, Division of Endocrinology
- Intervention
- Human recombinant growth hormone(biological)
- Eligibility
- 4 years · All sexes
- Timeline
- 2013 – 2015
Study locations (1)
- University of Maryland School of Medicine, Baltimore, Maryland, United States
Collaborators
Children's Hospital of Philadelphia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01614171 on ClinicalTrials.gov